Loading
Life sciences · Journal article
Current Breast Cancer Reports · October 7, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Abstract Purpose of Review Breast cancer is the most common malignancy in reproductive-age women, and its incidence is rising fastest in those under 50 as early-stage survival exceeds 90%. This review synthesizes current evidence on fertility preservation in breast cancer, focusing on the safety, efficacy, and available options. Recent Findings Early referral for fertility preservation does not meaningfully delay treatment, and ovarian stimulation and assisted reproduction appear oncologically safe, including in hormone receptor–positive disease. Oocyte and embryo cryopreservation remain a mainstay technique, refined by random-start and double-stimulation protocols, while ovarian tissue cryopreservation and GnRH-agonist co-treatment can further extend options. Aromatase inhibitor-based stimulation limits estrogen exposure without reducing yield, and the POSITIVE trial showed that interrupting endocrine therapy to conceive does not compromise short-term outcomes. For hereditary carriers, preimplantation genetic testing reduces variant transmission. Summary Fertility preservation is a safe, effective, central component of breast cancer care in reproductive aged patients who desire the option for biological offspring in the future. The principal remaining barriers are structural, including cost, coverage, and access disparities.